Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.98 |
| ▸ | DRD1 | P21728 | 5/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.98 |
| ▸ | HRH1 | P35367 | 5/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.98 |
| ▸ | HTR2B | P41595 | 5/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL4775632 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29358280 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL28763 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29278843 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1375329 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL5091769 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29279662 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364010-A1 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | WOODWARD SPECIALTY LLC (PR) | 2023-11-16 | — | — | US | disclosed |
| US-11752100-B2 | Intranasal delivery of olanzapine by precision olfactory device | IMPEL PHARMACEUTICALS INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220183965-A1 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | ALTER DOMUS (US) LLC | 2022-06-16 | — | — | US | disclosed |
| US-11278492-B2 | Intranasal delivery of olanzapine by precision olfactory device | IMPEL NEUROPHARMA, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3735223-A1 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | Impel Neuropharma Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-111836615-A | Intranasal delivery of olanzapine by precision nasal device | 英倍尔药业股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-20190240150-A1 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | ALTER DOMUS (US) LLC | 2019-08-08 | — | — | US | disclosed |
| WO-2019136308-A1 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | IMPEL NEUROPHARMA, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-9839622-B2 | Methods of treating hypothalamic obesity | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150150840-A1 | Methods of Treating Hypothalamic Obesity | ZAFGEN, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| EP-2846792-A1 | TREATING HYPOTHALAMIC OBESITY WITH METAP2 INHIBITORS | Zafgen, Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169857-A1 | TREATING HYPOTHALAMIC OBESITY WITH METAP2 INHIBITORS | ZAFGEN, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20050208156-A1 | Plants extracts and the use thereof | LICHTWER PHARMA GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150840-A1 | Methods of Treating Hypothalamic Obesity | METAP2, HCRTR2, MC4R | DRD2 2029/4885HTR2A 103/4885HTR2C 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.